Cytogenetic and molecular genetic alterations in hepatocellular carcinoma

Acta Pharmacologica Sinica

Volumn 26, Issue 6, 2005, Pages 659-665

  Lau, Sze Hang ^a   Guan, Xin Yuan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chromosome aberrations; Hepatocellular carcinoma; Oncogenes; Tumor suppressor genes

Indexed keywords

CANCER SCREENING; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 4Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME GAIN; CHROMOSOME LOSS; CHROMOSOME MAP; CHROMOSOME NUMBER; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DNA MICROARRAY; HETEROZYGOSITY LOSS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME MAPPING; GENE AMPLIFICATION; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES;

EID: 20444393130     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00126.x     Document Type: Review

References (68)

1. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001; 82: 77-100.
2. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
4. Miteiman F, Kaneko Y, Trent J. Human gene mapping 11: report of the committee on chromosome changes in neoplasia. Cytogenet Cell Genet 1991; 58: 1053-79.
5. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34: 369-76.
6. Yunis JJ, Ramsay N. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 1978; 132: 161-3.
7. Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 1976; 17: 47-56.
8. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-21.
9. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997; 18: 59-65.
10. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 37-43.
11. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999; 29: 1858-62.
12. Guan XY, Fang Y, Sham JS, Kwong DL, Zhang Y, Liang Q, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000; 29: 110-6.
13. Chang J, Kim NG, Piao Z, Park C, Park KS, Paik YK, et al. Assessment of chromosomal losses and gains in hepatocellular carcinoma assessment of chromosomal losses and gains in hepatocellular carcinoma. Cancer Lett 2002; 182: 193-202.
14. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992; 51: 862-8.
15. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 2927-33.
16. Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer. 1998; 75: 29-33.
17. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: Coleman WB, Tsongalis GJ, editors. The Molecular Basis of Human Cancer. Totowa, NJ: Humana Press; 2001. p 269-346.
18. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002; 95: 2346-52.
19. Qin LX, Tang ZY, Sham JS, Ma ZC, Ye SL, Zhou XD, et al. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 1999; 59: 5662-5.
20. Nishimura T, Nishida N, Itoh T, Komeda T, Fukuda Y, Ikai I, et al. Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes Cancer 2004; 42: 34-43.
21. Nishimura T, Nishida N, Itoh T, Kuno M, Minata M, Komeda T, et al. Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. Genes Chromosomes Cancer 2002; 35: 329-39.
22. Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, et al. Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes overexpression. J Hepatol 2003; 38: 298-306.
23. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 1999; 39: 79-86.
24. Tai ALS, Yan WS, Fang Y, Xie D, Sham JST, Guan XY. Recurrent chromosomal imbalances in non small cell lung cancer: the association of 1q amplification and tumor recurrence. Cancer 2004; 100: 1918-27.
25. Kwong D, Lam A, Guan XY, Law S, Tai A, Sham J. Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Human Pathol 2004; 35: 309-16.
26. Fong Y, Guan XY, Guo Y, Deng M, Liang Q, Li H, et al. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization (CGH). Genes Chromosomes Cancer 2001; 30: 254-60.
27. Sham JST, Tang TCM, Fang Y, Sun L, Qin LX, Xie D, Guan XY. Recurrent chromosome alterations in primary ovarian carcinoma of Chinese women. Cancer Genet Cytogenet 2002; 133: 39-44.
28. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998; 21: 177-84.
29. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003; 38: 1242-9.
30. Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-113.2 in breast cancer. Cancer Res 1996; 56: 3446-50.
31. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a novel estrogen receptor co-activator amplified in breast and ovarian cancer. Science 1997; 277: 965-8.
32. Piao Z, Park C, Park JH, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer 1998; 79: 356-60.
33. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Onda M, et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1999; 25: 284-9.
34. Jou YS, Lee CS, Chang YH, Hsiao CF, Chen CF, Chao CC, et al. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res 2004; 64: 3030-6.
35. Yeh SH, Lin MW, Lu SF, Wu DC, Tsai SF, Tsai CY, et al. Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 2004; 40: 847-54.
36. McGowan-Jordan IJ, Speevak MD, Blakey D, Chevrette M. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res 1994; 54: 2568-72.
37. Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 2004; 23: 4903-10.
38. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000; 32: 721-7.
39. Yan J, Yu Y, Wang N, Chang Y, Ying H, Liu W, et al. LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 2004; 23: 1939-49.
40. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998; 58: 2196-9.
41. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-51.
42. Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene. 2004; 23: 1308-13.
43. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, et al. Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 1995; 10: 891-5.
44. Levy A, Dang UC, Bookstein R. High-density screen of human tumor cell lines for homozygous deletions of loci on chromosome arm 8p. Genes Chromosomes Cancer 1999; 24: 42-7.
45. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998; 391: 295-8.
46. Goeman F, Thormeyer D, Abad M, Serrano M, Schmidt O, Palmero I, et al. Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells: involvement of two silencing domains and effect of Ras. Mol Cell Biol 2005; 25: 422-31.
47. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278: 10 824-30.
48. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Vihko P. Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br J Cancer 1999; 79: 156-60.
49. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416-9.
50. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002; 36: 692-701.
51. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Tajiri T, et al. Identification of a 1-Mb common region at 16q24. 1-24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer 2000; 28: 38-44.
52. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 2004; 91: 753-9.
53. Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, et al. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 1994; 54: 4200-6.
54. He QJ, Zeng WF, Sham JST, Xie D, Yang XW, Lin HL, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet 2003; 144: 112-8.
55. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
56. Yumoto Y, Hanafusa T, Hada H, Morita T, Ooguchi S, Shinji N, et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 179-85.
57. Guan XY, Sham JST, Tai LS, Fang Y, Li H, Liang Q. Evidence for another tumor suppressor gene at 17p13.3 distal to p53 in hepatocellular carcinoma. Cancer Genet Cytogenet 2003; 140: 45-8.
58. Qin WX, Wan F, Sun FY, Zhang PP, Han LW, Huang Y, et al. Cloning and characterization of a novel gene (C17orf25) from the deletion region on chromosome 17p13.3 in hepatocellular carcinoma. Cell Res 2001; 11: 209-16.
59. Pollack JR, Iyer VR. Characterizing the physical genome. Nat Genet 2002; 32: 515-21.
60. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-11.
61. Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003; 12: R145-52.
62. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP. Genomic microarrays in the spotlight. Trends Genet 2004; 20: 87-94.
63. Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 2004; 17: 617-22.
64. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004; 36: 299-303.
65. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol 2000; 18: 1001-5.
66. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060-71.
67. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H, et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004; 64: 7263-70.
68. Paul MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 21: 1-11.